Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus
Journal article, 2011
Single-nucleotide polymorphisms upstream of the interleukin 28B (interferon lambda 3) gene (IL28B) strongly influence treatment efficacy in patients carrying hepatitis C virus (HCV) of genotype 1. In patients receiving 12 or 24 weeks of interferon-ribavirin therapy for infection with genotype 2 or 3 (n = 341), we found that rs12979860 strikingly determined the first phase of viral elimination (P < .001). In patients treated for 24 weeks, rs12979860 also predicted the rate of sustained virologic response (P = .02), especially among those with high baseline HCV RNA levels (P = .002) or older than 45 years (P = .01). Patients carrying CCrs12979860 had higher baseline HCV RNA levels (P < .001) and did not, when treated for 12 weeks, achieve sustained virologic response more often than those carrying CTrs1297986 or TTrs1297986. The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment.
ribavirin
il28b
Author
Magnus Lindh
University of Gothenburg
Martin Lagging
University of Gothenburg
Martti Färkkilä
University of Helsinki
Nina Langeland
University of Bergen
Kristine Mørch
University of Bergen
Staffan Nilsson
University of Gothenburg
Chalmers, Mathematical Sciences, Mathematical Statistics
Gunnar Norkrans
University of Gothenburg
Court Pedersen
University of Southern Denmark
Mads Rauning Buhl
Aarhus University
Johan Westin
University of Gothenburg
Kristoffer Hellstrand
University of Gothenburg
Published in
Journal of Infectious Diseases
0022-1899 (ISSN) 1537-6613 (eISSN)
Vol. 203 Issue 12 p. 1748-1752Categorizing
Subject Categories (SSIF 2011)
Dermatology and Venereal Diseases
Identifiers
DOI
10.1093/infdis/jir193